LI Cheng-peng, HAO Chun-yi, YANG Dong-yang. Inspiring,But Not Blindly Optimistic: Appraisal of FOLFIRINOX Regimen as Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(5): 267-270. DOI: 10.12019/j.issn.1671-5144.2019.05.004
|
Citation:
|
LI Cheng-peng, HAO Chun-yi, YANG Dong-yang. Inspiring,But Not Blindly Optimistic: Appraisal of FOLFIRINOX Regimen as Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(5): 267-270. DOI: 10.12019/j.issn.1671-5144.2019.05.004
|
LI Cheng-peng, HAO Chun-yi, YANG Dong-yang. Inspiring,But Not Blindly Optimistic: Appraisal of FOLFIRINOX Regimen as Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(5): 267-270. DOI: 10.12019/j.issn.1671-5144.2019.05.004
|
Citation:
|
LI Cheng-peng, HAO Chun-yi, YANG Dong-yang. Inspiring,But Not Blindly Optimistic: Appraisal of FOLFIRINOX Regimen as Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(5): 267-270. DOI: 10.12019/j.issn.1671-5144.2019.05.004
|
DownLoad: